Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2016 1
2017 1
2018 3
2019 4
2020 3
2021 7
2022 8
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Corrigendum: Feasibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen self-testing in school and summer camp attendees.
Colom-Cadena A, Martínez-Riveros H, Bordas A, Alonso-García L, Montoro-Fernández M, Romano-deGea P, Vidal-Alaball J, Solà-Segura E, Llibre JM, Revollo B, Casabona J, Agustí C. Colom-Cadena A, et al. Among authors: revollo b. Front Pediatr. 2024 Jan 5;11:1353806. doi: 10.3389/fped.2023.1353806. eCollection 2023. Front Pediatr. 2024. PMID: 38250593 Free PMC article.
Predictors of poor health-related quality of life among people living with HIV aged ≥60 years in the PISCIS cohort: Findings from the Vive+ project.
Bruguera A, Egea-Cortés L, Mesías-Gazmuri J, Palacio-Vieira J, Forero CG, Miranda C, Saumoy M, Fernández E, Navarro G, Orti A, Miró JM, Casabona J, Reyes-Urueña J; PISCS Study Group. Bruguera A, et al. HIV Med. 2024 Apr;25(4):424-439. doi: 10.1111/hiv.13590. Epub 2023 Dec 13. HIV Med. 2024. PMID: 38092529
Cohort Profile: PISCIS, a population-based cohort of people living with HIV in Catalonia and Balearic Islands.
Bruguera A, Nomah D, Moreno-Fornés S, Díaz Y, Aceitón J, Reyes-Urueña J, Ambrosioni J, Llibre JM, Falcó V, Imaz A, Fanjul F, Navarro G, Pere D, León E, Mera A, Miró JM, Casabona J; PISCIS Cohort Group. Bruguera A, et al. Int J Epidemiol. 2023 Aug 2;52(4):e241-e252. doi: 10.1093/ije/dyad083. Int J Epidemiol. 2023. PMID: 37403345 No abstract available.
Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy.
Bernal S, Puertas MC, Morón-López S, Cranston RD, Urrea V, Dalmau J, Salgado M, Gálvez C, Erkizia I, McGowan I, Scherrer D, Revollo B, Sirera G, Santos JR, Clotet B, Paredes R, Martinez-Picado J. Bernal S, et al. Among authors: revollo b. J Infect Dis. 2023 Nov 2;228(9):1280-1291. doi: 10.1093/infdis/jiad251. J Infect Dis. 2023. PMID: 37395474 Free PMC article.
Feasibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen self-testing in school and summer camp attendees.
Colom-Cadena A, Martínez-Riveros H, Bordas A, Alonso-García L, Montoro-Fernández M, Romano-deGea P, Vidal-Alaball J, Solà-Segura E, Llibre JM, Revollo B, Casabona J, Agustí C. Colom-Cadena A, et al. Among authors: revollo b. Front Pediatr. 2023 Jan 10;10:975454. doi: 10.3389/fped.2022.975454. eCollection 2022. Front Pediatr. 2023. PMID: 36741092 Free PMC article.
Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimens.
Burgos J, Moreno-Fornés S, Reyes-Urueña J, Bruguera A, Martín-Iguacel R, Raventos B, Llibre JM, Imaz A, Peraire J, Orti AJ, Dalmau D, Casabona J, Miró JM, Falcó V; PISCIS study group. Burgos J, et al. J Antimicrob Chemother. 2022 Dec 23;78(1):108-116. doi: 10.1093/jac/dkac361. J Antimicrob Chemother. 2022. PMID: 36308326
Prevention of Anal Cancer.
Revollo B, Videla S, Llibre JM. Revollo B, et al. N Engl J Med. 2022 Aug 18;387(7):666. doi: 10.1056/NEJMc2209237. N Engl J Med. 2022. PMID: 36070726 No abstract available.
Protection Against Severe Clinical Outcomes With Adenovirus or Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Patients Hospitalized With Coronavirus Disease 2019.
Llibre JM, Revollo B, Aguilar S, Calomarde-Gomez C, Bruguera A, Martin-Iguacel R. Llibre JM, et al. Among authors: revollo b. J Infect Dis. 2022 Sep 13;226(5):938-940. doi: 10.1093/infdis/jiac256. J Infect Dis. 2022. PMID: 35763360 Free PMC article. No abstract available.
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study.
Nomah DK, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco-Hidalgo RM, Casabona J, Domingo P, Navarro J, Imaz A, Deig E, Navarro G, Llibre JM, Miro JM; PISCIS study group. Nomah DK, et al. J Antimicrob Chemother. 2022 Jul 28;77(8):2265-2273. doi: 10.1093/jac/dkac177. J Antimicrob Chemother. 2022. PMID: 35678461 Free PMC article.
Gut microbiome signatures linked to HIV-1 reservoir size and viremia control.
Borgognone A, Noguera-Julian M, Oriol B, Noël-Romas L, Ruiz-Riol M, Guillén Y, Parera M, Casadellà M, Duran C, Puertas MC, Català-Moll F, De Leon M, Knodel S, Birse K, Manzardo C, Miró JM, Clotet B, Martinez-Picado J, Moltó J, Mothe B, Burgener A, Brander C, Paredes R; BCN02 Study Group. Borgognone A, et al. Microbiome. 2022 Apr 11;10(1):59. doi: 10.1186/s40168-022-01247-6. Microbiome. 2022. PMID: 35410461 Free PMC article. Clinical Trial.
32 results